Affluent Medical announces its 2023 results and the progression of its clinical activities

Affluent Medical, a French company in the MedTech sector, has published its financial results for the year 2023 and provided significant updates regarding its research and development activities. The company has made notable advances in clinical studies of its innovative medical devices, including KaliosTM, Epygon and Artus.

KaliosTM, a percutaneously adjustable mitral annulus, demonstrated good safety and efficacy results in the Optimise II pivotal study. This performance encourages the company to focus on the US market, anticipating a regulatory submission to the FDA. At the same time, the Epygon valve successfully completed its first implantation, supporting its potential in the endovascular mitral valve market. For the Artus device, intended for the treatment of urinary incontinence, a first human implantation was successful and a European study is underway.

Financially, Affluent Medical recorded a capital increase of 13.7 million euros at the beginning of March, with significant advances from its shareholders supporting its operations until the end of July 2024. These funds facilitate the advancement of its projects research and development and future commercialization.